Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported second quarter 2024 financial results, recent business highlights and key future milestones for 2024.

“Building on the recent BLA acceptance with Priority Review for tab-cel, we are making significant progress with the agency toward the targeted action date of January 15, 2025, while supporting our partner Pierre Fabre as they prepare for the U.S. launch,” said Pascal Touchon, President and Chief Executive Officer of Atara. “During the quarter, we continued the clinical development of our lead CAR T program, ATA3219, and remain on track to deliver key value-creating milestones within the next 12 months. This is highlighted by the first data from our non-Hodgkin lymphoma study expected in the first quarter of 2025, which we believe will provide a window into the potential of ATA3219 in autoimmune diseases. On that front, we plan to initiate our ATA3219 Systemic Lupus Erythematosus study in the fourth quarter, including the non-lymphodepleted cohort, with first data expected in mid-2025.”